Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brendan O'Grady
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 7
- Beta
- 4.20
- Country
- IL
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 9.43
Financials
Net Income
$-5.94MEBITDA
$-5.95MFree Cash Flow
$-1.99MEPS (diluted)
$-0.54Shares Outstanding (diluted)
11.07M+60.7%Operating Expenses
$6.04MCash & Debt
$11.82MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-5.86M | $-0.72 |
| 2024 | $0.00 | $-1.53M | $-0.17 |
| 2023 | $0.00 | $-1.05M | $-0.12 |
| 2022 | $0.00 | $-1.71M | $-0.19 |
Valuation
NSRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·7d ago·Neutral
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
Nasus Pharma Announces Transition of Chief Financial Officer TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry.
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
…Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced its financial results for the six months ending June 30, 2026 and provided a corporate update.
View source ↗
Earnings
Typical surprise -100.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 17$-0.54 vs $-0.27miss
Estimates and results for NSRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NSRX officers and directors.
- Bought
- $62k
- Sold
- —
3 trades
0 trades
- Teleman Dan Benjaminbought
- Teleman Dan Benjaminbought
- Teleman Dan Benjaminbought
20 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NSRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.